VERTEX PHARMACEUTICALS INC / MA Defined Contribution Plan, Cost
VERTEX PHARMACEUTICALS INC / MA (VRTX) reported Defined Contribution Plan, Cost of $63.10 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-13.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:DefinedContributionPlanCostRecognized · last filed 2026-02-13
- VERTEX PHARMACEUTICALS INC / MA defined contribution plan, cost for fiscal 2025 was $63.10M, a 20.65% increase from fiscal 2024.
- VERTEX PHARMACEUTICALS INC / MA defined contribution plan, cost for fiscal 2024 was $52.30M, a 19.95% increase from fiscal 2023.
- VERTEX PHARMACEUTICALS INC / MA defined contribution plan, cost for fiscal 2023 was $43.60M, a 19.78% increase from fiscal 2022.
- VERTEX PHARMACEUTICALS INC / MA defined contribution plan, cost for fiscal 2022 was $36.40M, a 21.74% increase from fiscal 2021.
| Period end | Defined Contribution Plan, Cost 12 month | Defined Contribution Plan, Cost 12 month as first filed |
|---|---|---|
| 2025-12-31 | $63.10M 10-K · filed 2026-02-13 | |
| 2024-12-31 | $52.30M 10-K · filed 2026-02-13 | |
| 2023-12-31 | $43.60M 10-K · filed 2026-02-13 | |
| 2022-12-31 | $36.40M 10-K · filed 2025-02-13 | $27.50M 10-K · filed 2023-02-10 |
| 2021-12-31 | $29.90M 10-K · filed 2024-02-15 | $21.80M 10-K · filed 2022-02-09 |
| 2020-12-31 | $19.20M 10-K · filed 2023-02-10 | |
| 2019-12-31 | $15.80M 10-K · filed 2022-02-09 | |
| 2018-12-31 | $13.90M 10-K · filed 2021-02-11 | |
| 2017-12-31 | $12.30M 10-K · filed 2020-02-13 | |
| 2016-12-31 | $11.80M 10-K · filed 2019-02-13 | |
| 2015-12-31 | $12.80M 10-K · filed 2018-02-15 | |
| 2014-12-31 | $12.00M 10-K · filed 2017-02-23 | |
| 2013-12-31 | $12.60M 10-K · filed 2016-02-16 | $5.93M 10-K · filed 2014-02-11 |
| 2012-12-31 | $10.26M 10-K · filed 2015-02-13 | |
| 2011-12-31 | $8.62M 10-K · filed 2014-02-11 | |
| 2010-12-31 | $6.55M 10-K · filed 2013-03-01 | |
| 2009-12-31 | $6.04M 10-K · filed 2012-02-22 | |
| 2008-12-31 | $5.03M 10-K · filed 2011-02-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |